Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment crawled date : 2022 - 09 - 14 save search
USD 7.22 Bn growth expected in Myopia and Presbyopia Treatment Market -- Evolving Opportunities with AbbVie Inc. and Alcon Inc.
Published: 2022-09-14 (Crawled : 21:00) - prnewswire.com
ALC | $79.43 1.22% 760K
|
Health Technology
|
| O: 0.71%
H: 0.82%
C: -0.31%
ABBV | News | $165.97 0.8% 3.1M
|
Health Technology
|
| O: 0.32%
H: 2.79%
C: 1.8%
treatment expected growth presbyopia market
It All Comes Down To Science And Research With The Efficacy Of Jupiter Wellness’s Lineup Of Skin And Hair Treatment Drugs
Published: 2022-09-14 (Crawled : 19:00) - jupiterwellnessinc.com
WMT | News | $59.39 0.22% 7.1M
|
Retail Trade
|
| O: 0.1%
H: 0.07%
C: -1.17%
treatment research skin
Jupiter Wellness’s Booster Drug Has Potential To Increase Hair Loss Treatments’ Efficacy By Enhancing Crucial Enzyme Enrichment Capacity by 7x
Published: 2022-09-14 (Crawled : 19:00) - jupiterwellnessinc.com
UNLYF | $47.95 740
|
Consumer Non-Durables
|
| O: -1.57%
H: 0.09%
C: 0.09%
UL | $47.24 0.83% 3.9M
|
Consumer Non-Durables
|
| O: -1.0%
H: 0.55%
C: -0.15%
JNJ | News | $147.895 1.48% 5.8M
|
Health Technology
|
| O: 1.17%
H: 0.99%
C: 0.38%
drug capacity potential
Sermonix Pharmaceuticals Shares Details of First-Ever Known Durable Complete Clinical Response in a Metastatic ER+/HER2- Breast Cancer Patient With an ESR1 Mutation After Prior CDK4/6 Inhibitor Treatment
Published: 2022-09-14 (Crawled : 16:00) - biospace.com/
LGND | $72.52 91K
|
Health Technology
|
| O: 0.44%
H: 0.48%
C: -2.07%
treatment response cancer esr1 mutation her2- her2
Timber Pharmaceuticals Receives Positive Opinion on Orphan Designation from European Medicines Agency for TMB-001 for Treatment of Autosomal Recessive Congenital Ichthyosis
Published: 2022-09-14 (Crawled : 14:20) - biospace.com/
TMBR | $0.3426 -2.69% 3K
|
Health Technology
|
| O: 5.69%
H: 34.23%
C: 7.31%
tmb-001 treatment designation positive
TRACON Pharmaceuticals Announces Fast Track Designation by the FDA for Envafolimab for the Treatment of the Soft Tissue Sarcoma Subtypes of UPS and MFS
Published: 2022-09-14 (Crawled : 14:20) - biospace.com/
TCON | $2.01 -4.74% 130K
|
Health Technology
|
| O: 4.21%
H: 1.52%
C: -4.04%
treatment fda designation soft tissue fast track designation
Centessa Pharmaceuticals Announces Orphan Drug Designation Granted to SerpinPC for the Treatment of Hemophilia B
Published: 2022-09-14 (Crawled : 14:00) - biospace.com/
CNTA | $10.42 -1.05% 74K
|
Manufacturing
|
| O: 0.94%
H: 9.53%
C: 7.91%
treatment designation drug granted
Amylyx Pharmaceuticals Announces Donated CENTAUR Clinical Trial Data Now Available to Help Advance Science in ALS for Future Treatments and Discoveries
Published: 2022-09-14 (Crawled : 14:00) - biospace.com/
AMLX | $1.88 -5.05% 1.2M
|
|
| O: -0.95%
H: 5.8%
C: 3.24%
als trial
GentiBio To Present Preclinical Data Demonstrating Technical Progress to Engineer Regulatory T Cells for the Prevention and Treatment of Autoimmune Diseases
Published: 2022-09-14 (Crawled : 14:00) - biospace.com/
IBIO | $1.73 -2.26% 77K
|
Health Technology
|
| O: -0.97%
H: 4.16%
C: -4.89%
treatment preclinical
Adverum Biotechnologies Announces First Subject Dosed with Ixo-vec in the Phase 2 LUNA Trial for the Treatment of Wet Age-Related Macular Degeneration
Published: 2022-09-14 (Crawled : 14:00) - biospace.com/
ADVM | $11.065 -0.76% 69K
|
Health Technology
|
| O: 0.0%
H: 7.55%
C: 2.83%
treatment macular trial phase 2
eFFECTOR Therapeutics Doses First Patient in Second Cohort of Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID-19
Published: 2022-09-14 (Crawled : 12:20) - globenewswire.com
EFTR | $1.645 -7.58% 170K
|
|
| O: 3.58%
H: 2.95%
C: -4.62%
covid-19 treatment trial therapeutics phase 2b
Surface Oncology to Present Preclinical Data Highlighting the IL-27 Gene Expression Signature in Treatment-Resistant Cancers at the 10th Annual International Cytokine and Interferon Society Meeting
Published: 2022-09-14 (Crawled : 12:00) - globenewswire.com
SURF | $1.07 -0.93% -1.41% 0
|
Health Technology
|
| O: 0.76%
H: 2.26%
C: 0.0%
il-27 preclinical meeting international
Macular Degeneration Treatment Global Market to Reach $10.65 Billion by 2026 at a CAGR of 7.15%
Published: 2022-09-14 (Crawled : 10:00) - prnewswire.com
GLAXF | $20.2 510
|
Health Technology
|
| O: -4.98%
H: 7.63%
C: 2.67%
NVS | $94.285 1.85% 1.6M
|
Health Technology
|
| O: -0.55%
H: 0.42%
C: -0.72%
GSK | $39.585 0.8% 1.1M
|
Health Technology
|
| O: -0.6%
H: 0.41%
C: -0.76%
BHC | $8.63 0.35% 2.1M
|
Health Technology
|
| O: 0.41%
H: 11.64%
C: 6.22%
RGNX | $15.775 -2.08% 340K
|
Health Technology
|
| O: 0.38%
H: 2.53%
C: 1.48%
treatment global macular market
Syros Receives FDA Orphan Drug Designation for SY-5609 for the Treatment of Pancreatic Cancer
Published: 2022-09-13 (Crawled : 01:00) - biospace.com/
SYRS | $4.45 -5.72% 110K
|
Health Technology
|
| O: 21.87%
H: 3.93%
C: -13.94%
sy-5609 treatment fda designation drug cancer pancreatic
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Canada
Published: 2022-09-13 (Crawled : 00:00) - globenewswire.com
MNOV | $1.4 9.6K
|
Health Technology
|
| O: 2.82%
H: 2.74%
C: -1.37%
mn-001 treatment patent canada hypercholesterolemia
Gainers vs Losers
| 70% | 30% |
Top 10 Gainers
AGBA | News | $1.305 226.25% 130M
|
Finance
EGOX | $0.0503 39.72% 320M
|
RWOD | $10.52 31.56% 5.9M
|
n/a
ZCMD | $1.905 31.38% 30M
|
Commercial Services
MRDB 4 | $0.536 27.65% 2M
|
n/a
BSFC | $0.0822 27.64% 75M
|
Manufacturing
TPET | $0.4121 25.68% 45M
|
n/a
NVFY | $2.65 25.59% 33M
|
Consumer Durables
INDO | $5.1 25.0% 15M
|
Energy Minerals
CHRO | $1.53 24.9% 100K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.